

	Reimbursement Policy
--	----------------------

Subject: [Drug Screen Testing]

- Policy Section: [Laboratory]

<ul style="list-style-type: none"> Last Approval Date: [06/25/2021] 	<ul style="list-style-type: none"> Effective Date: [03/01/20[90 days from communication]] 	<ul style="list-style-type: none"> Committee Approval Obtained: [03/15/19] 	<ul style="list-style-type: none"> Section: [Laboratory]
--	--	---	---

~~*****The most current version of our reimbursement policies can be found on our provider website. If you are using a printed version of this policy, please verify the information by going to <https://providers.healthyblucla.com>.*****~~

~~These policies serve as a guide to assist you in accurate claim submissions and to outline the basis for reimbursement by Healthy Blue if the service is covered by a member's Healthy Louisiana benefit plan. The determination that a service, procedure, item, etc. is covered under a member's benefit plan is not a determination that you will be reimbursed. Services must meet authorization and medical necessity guidelines appropriate to the procedure and diagnosis as well as to the member's state of residence. You must follow proper billing and submission guidelines. You are required to use industry standard, compliant codes on all claim submissions. Services should be billed with CPT codes, HCPCS codes and/or revenue codes. The codes denote the services and/or procedures performed. The billed code(s) are required to be fully supported in the medical record and/or office notes. Unless otherwise noted within the policy, our policies apply to both participating and nonparticipating providers and facilities.~~

~~If appropriate coding/billing guidelines or current reimbursement policies are not followed, Healthy Blue may:~~

- ~~Reject or deny the claim.~~
- ~~Recover and/or recoup claim payment.~~

~~Healthy Blue reimbursement policies are developed based on nationally accepted industry standards and coding principles. These policies may be superseded by mandates in provider, state, federal or CMS contracts and/or requirements. System logic or setup may prevent the loading of policies into the claims platforms in the same manner as described; however, Healthy Blue strives to minimize these variations.~~

Healthy Blue reserves the right to review and revise our policies periodically when necessary. When there is an update, we will publish the most current policy to this site.

Policy	<p>Healthy Blue allows reimbursement for properly ordered definitive drug screening of 1 to 14 drug classes when submitted on the same date of service as presumptive drug testing by instrumented chemistry analyzers for the same member by an independent clinical laboratory with a place of service 81. Definitive drug testing for fifteen or more drug classes will not be separately reimbursed when performed on the same date of service as presumptive testing.</p> <p>Definitive drug testing may be done to confirm a negative presumptive test or to identify substances when there is no presumptive test available. Provider's documentation and member's medical records should reflect that the test was properly ordered and support that the order was based on the result of the presumptive test.</p> <p>When a reference lab (POS = 81) performs both presumptive and definitive tests on the same date of service, records should reflect that the ordering/treating provider issued a subsequent order for definitive testing based on the results of the presumptive tests.</p> <p>Healthy Blue does not allow reimbursement for employment/ pre-employment drug screening.</p>
History	<ul style="list-style-type: none"> ● Initial approval 03/15/19 and effective date 03/01/20
References and Research Materials	<p>This policy has been developed through consideration of the following:</p> <ul style="list-style-type: none"> ● CMS ● State Medicaid ● State contracts ● Optum, 2018
Definitions	<ul style="list-style-type: none"> ● Presumptive Drug Class Screening: screening used to identify possible use or non-use of a drug or drug class (presumptive drug screening may or may not be followed by definitive drug class screening); presumptive drug testing is either done on a random basis or for cause, the latter which should be documented in the medical record ● Definitive Drug Class Screening: screening which includes qualitative (drug is present or absent), semi-quantitative or quantitative (measured) tests to identify possible use or non-use of a specific drug; typically therapeutic drug assay procedures are quantitative tests ● General Reimbursement Policy Definitions
Related Policies	<ul style="list-style-type: none"> ● None
Related Materials	<ul style="list-style-type: none"> ● None

Visit our provider website for the most current version of our reimbursement policies. If you are using a printed version of this policy, please verify the information by going to <https://provider.healthybluelouisiana.com>.

Disclaimer

These policies serve as a guide to assist you in accurate claim submissions and to outline the basis for reimbursement by Healthy Blue if the service is covered by a member's Healthy Louisiana benefit plan. The determination that a service, procedure, item, etc. is covered under a member's benefit plan is not a determination that you will be reimbursed. Services must meet authorization and medical necessity guidelines appropriate to the procedure and diagnosis. You must follow proper billing and submission guidelines. You are

required to use industry standard, compliant codes on all claim submissions. Services should be billed with CPT® codes, HCPCS codes, and/or revenue codes. The codes denote the services and/or procedures performed. The billed code(s) are required to be fully supported in the medical record and/or office notes. Unless otherwise noted within the policy, our policies apply to both participating and nonparticipating providers and facilities.

If appropriate coding/billing guidelines or current reimbursement policies are not followed, Healthy Blue may:

- Reject or deny the claim.
- Recover and/or recoup claim payment.

Healthy Blue reimbursement policies are developed based on nationally accepted industry standards and coding principles.

Healthy Blue reserves the right to review and revise our policies periodically when necessary. When there is an update, we will publish the most current policy to our provider website.

Policy

Healthy Blue allows reimbursement for properly ordered definitive drug testing of 1 to 14 drug classes when performed by an independent laboratory (POS 81) on the same date of service as presumptive drug testing by instrumented chemistry analyzers for the same member. Definitive drug testing for fifteen or more drug classes requires a subsequent order from the treating provider and will not be separately reimbursed when performed on the same date of service as presumptive testing.

Definitive drug testing may be used to detect specific substances not identified by presumptive methods and to refine the accuracy of the presumptive test results. Provider's documentation and member's medical records should reflect that the test was properly ordered. For cases where the definitive testing is confirmatory, the provider's documentation should support that the order was based on the result of the presumptive test.

Non-Reimbursable

Healthy Blue does not allow separate reimbursement for specimen validity testing when utilized for drug screening. Specimen validity testing is included in the presumptive and definitive drug testing CPT and HCPCS code descriptions. No modifiers will override this edit.

Healthy Blue does not allow reimbursement for employment/
pre-employment drug screening.

Coding

<u>Policy Section</u>	<u>Code(s)</u>	<u>Comments</u>
<u>N/A</u>	<u>N/A</u>	<u>Standard correct coding applies.</u>

Policy History

<u>Date ↑</u>	<u>Specific action on date entered</u>
<u>(06/25/21)</u>	<u>Biennial review approved 06/25/2021 and effective [TBD]: policy language updated to not allow separate reimbursement for specimen validity testing</u>
<u>(03/15/19)</u>	<u>Initial approval 03/15/19 and effective date 02/01/20</u>

References and Research Materials

This policy has been developed through consideration of the following:

- [CMS](#)
- [State Medicaid](#)
- [State contracts](#)
- [Optum360, 2020](#)

Definitions

Presumptive Drug Class Screening	Screening used to identify possible use or non-use of a drug or drug class (presumptive drug screening may or may not be followed by definitive drug class screening); presumptive drug testing is either done on a random basis or for cause, the latter of which should be documented in the medical record
Definitive Drug Class Screening	Screening which includes qualitative (drug is present or absent), semi-quantitative or quantitative (measured) tests to identify possible use or non-use of a specific drug; typically, therapeutic drug assay procedures are quantitative tests
Specimen Validity Testing	Testing used to detect for substitution, adulteration or dilution of a urine drug test
General Reimbursement Policy Definitions	

Related Policies and Materials

- [None](#)